

Financial Assistance through the Wisconsin Tuberculosis Program




Financial Assistance through the Wisconsin Tuberculosis (TB) Program

- Wisconsin TB Dispensary Program and Contracting
- Reimbursement for Clinical Services
- Medication Orders and Refills
- Reimbursement for Pharmacy Services
- TB Treatment Assistance Program

Wisconsin TB Dispensary Program (WTBDP) Purpose Statement

To ensure that all persons in Wisconsin with suspected or confirmed active TB disease or latent TB infection (LTBI) can receive appropriate evaluation, treatment, and monitoring, regardless of insurance availability.




The WTBDP reimburses services for the uninsured and underinsured.






TB Dispensary Contract


There are three steps to obtaining reimbursement.




TB Dispensary Contracting Process




TB Dispensary Contracting Process



TB Dispensary Contracting Process



Attachment B is the Clinical Services Plan.



An LHD must verify that the providers they list on Attachment B are:



Consistent with CDC guidelines.

Consistent with clinical standards of care.

Consistent with Wisconsin's goals for TB elimination.

Pharmacy Services Plan







Provision of Medications for TB/LTBI




Dispense, Deliver, Document




Attachment



Several helpful attachments are sent with the contract.




TB Dispensary Contract Cycle






Reimbursement for Clinical Services using the TB Ordering and Billing Interface (TOBI)


Access to TOBI




Reimbursement for clinical services in TOBI consists of four steps.




Step 1- Preauthorization Requests





Step 1- Preauthorization Requests





Step 2- Creating an invoice













Step 3- Review and Reimbursement of the Invoice



Step 4- Adjustments



Step 4- Adjustments

TUBERCULOSIS DISPENSARY INVOICE

STATE OF WISCON

s.252.10(7), Wis. Si Wisconsin Tuberculosis Progr Telephone: (608) 261-6;

FAX: (608) 266-0

Invoice ID : 0

Invoice Date : 4/8/2019 11:41:53 AM

Invoice Billed Amount : \$0

Invoice Approved Amount: : \$0

+ Adjustment (Credit) : \$0

- Adjustment (Debit) : \$0

Total Paid Amount : \$0

Changes in Reimbursement through the Wisconsin TB Dispensary Program

- Travel to visit clients is now reimbursable.
 - T0001-45 (45 minutes or more)
 - T0001-60 (over 60 minutes)
- Nurse Services Codes
 - Directly Observed Therapy (DOT)
 - Patient Education
 - Symptom and Treatment Monitoring
- Video DOT




Medication Orders and Refills

The medication request process is five steps.



Step 1- LHD Notification of LTBI or Active TB Case



Step 2- Submission of Initial Medication Request



Providers should submit the completed medication request form to the LHD.

Active TB: F-44000

LTBI: <u>F-00905</u>



LHDs should review orders before submission.



Weight



Qualifying Factor for Vitamin B6



Location for shipment





Reviewing the Medication Order

DEPARTMENT OF HEALTH SERVICES Division of Public Health F-00905 (12/2019)

TUBERCULOSIS INFECTION INITIAL REQUEST FOR MEDICATION


Fields marked with an asterisk (*) are required. Please complete patient information on pages 1 & 2.

STATE OF WISCONSIN

Wis. Stats § 252.10 (7) Wisconsin Tuberculosis Program Telephone: 608-261-6319 Page 1 of 5

SUBMIT COMPLETED FORM TO:		Health Department (LHD)			LHD Fax Number
*NAME – Patient (Last, First, Middle Initial) *Address (Street or Rural Route)					*Date of Birth (mm/dd/yyyy) *Telephone Number
*Sex	*Race	*Ethnicity ☐ Hispanic ☐ Non-Hispanic	*Weight		· · · · · · · · · · · · · · · · · · ·
Patient Insu	ırance İn	formation		**	
☐ Patient h	as no insi	urance + financial hardship: WI TE	3 Dispensary	covers entire cost.	
		nce + financial hardship (include p on insurance provider and number		insurance card): W	TTB Dispensary to cover co-pay
		nce and no financial hardship: WI e their own pharmacy.	TB Dispensa	ıry will not cover co	st but is available for consultation
*NAME – Clinician (Print clearly) NAME - Hospital/Clinic/Faci					acility
		V regional as the second to			

Reviewing the Medication Order



Reviewing the Medication Order

*MEDICATION ORDERS (Check mg/kg for patients with val Regimen	riable weight)		
Isoniazid and Rifapentine once per week via directly-ob	served therapy X 12	weeks	
☐ Isoniazid 900 mg and Rifapentine 900 mg	│ □ INH mg	g + Rifapentine	mg
Rifampin daily X 4 months (Generic Only) For dosing, see page 5.	☐ 600 mg	mg	mg
Isoniazid (INH) daily X 6-9 months (Generic Only) For dosing, see page 5.	☐ 300 mg	mg	mg
☐ Other:			
Other:			
MONITORING ORDERS1. Assess the patient at least monthly for side effects and me2. Other:	9		linician if present.
*SIGNATURE			
SIGNATURE – Clinician:	* [Date Prescription Orde	ered:
To be completed by Local Health Department			
WEDSS Disease Incident Number	Ship medication to	0:	I
Pharmacy: TB Dispensary Pharmacy Other, List			

Reviewing the Medication Order

F-00905 (Rev. 12/2019) Tuberculosis Infection Initial Request for Medication	Page 2 of 5
Patient Name:	Patient Reporter DI:
PATIENT INFORMATION - Please note the risk factors for infection patient must have risk factors for infection BEFORE having risk	ction, below. Remember when referring a patient for treatment that a of progression.
A. *Patient Risk Factors and Reasons for Treatment (check	all that apply) See page 4 for description.
 Risk for TB Infection ☐ Birth, residence or travel (for ≥ 1 month) in a country w • Includes any country other than the United States, or northern Europe. • Travel is of extended duration or including likely cor ☐ Close contact to someone with infectious TB disease 	Canada, Australia, New Zealand, or a country in western
Risk for Progression to TB Disease Human immunodeficiency virus (HIV) infection Current or planned immunosuppression including rece antagonist (e.g., infliximab, etanercept, or other), chroor other immunosuppressive medication in combination Other Mandated testing (e.g., employment, healthcare personal combination of the combination	onic steroids (equivalent of prednisone ≥ 15 mg/day for ≥ 1 month) on with risk for infection from above


Reviewing the Medication Order

2. Quantiferon™ (QFT) blood assay: Date Drawn: Results:	 T-S 		e Drawn:	Results: □Pos	sitive Negative Indeter	minate Invalid
3. Tuberculin Skin Test: Date Applied: Date Read: Results (induration only)						
A. Specimen (Sputum or BAL) Date Collected Results Smear PCR Cultur Other: D. *Chest Imaging: (Include copy of chest x-ray and/or CT report with this request, CXR needs to be within 6 months) Date: Results: Normal Abnormal Cavitary If chest imaging is abnormal and consistent with TB, three sputum samples should be submitted to the WSLH for sme and culture, before treatment for LTBI can begin. E. *Prior treatment for tuberculosis infection or disease? NO YES Please explain: F. Baseline blood tests, if applicable (ALT/AST, CBC, CMP, T. BIL, if preexisting liver disease) Test Date Result		The second secon			(d) (d)	
Smear PCR Cultur	192				Results (inc	duration only)
D. *Chest Imaging: (Include copy of chest x-ray and/or CT report with this request, CXR needs to be within 6 months) Date: Results: _ Normal _ Abnormal _ Cavitary If chest imaging is abnormal and consistent with TB, three sputum samples should be submitted to the WSLH for sme and culture, before treatment for LTBI can begin. E. *Prior treatment for tuberculosis infection or disease? NO YES Please explain: F. Baseline blood tests, if applicable (ALT/AST, CBC, CMP, T. BIL, if preexisting liver disease) Test Date Result	4.		Date Collected		PCR	Cultur
D. *Chest Imaging: (Include copy of chest x-ray and/or CT report with this request, CXR needs to be within 6 months) Date: Results: Normal Abnormal Cavitary If chest imaging is abnormal and consistent with TB, three sputum samples should be submitted to the WSLH for sme and culture, before treatment for LTBI can begin. E. *Prior treatment for tuberculosis infection or disease? NO YES Please explain: F. Baseline blood tests, if applicable (ALT/AST, CBC, CMP, T. BIL, if preexisting liver disease) Test Date Result						
D. *Chest Imaging: (Include copy of chest x-ray and/or CT report with this request, CXR needs to be within 6 months) Date: Results: Normal Abnormal Cavitary If chest imaging is abnormal and consistent with TB, three sputum samples should be submitted to the WSLH for sme and culture, before treatment for LTBI can begin. E. *Prior treatment for tuberculosis infection or disease? NO YES Please explain: F. Baseline blood tests, if applicable (ALT/AST, CBC, CMP, T. BIL, if preexisting liver disease) Test Date Result	-					
D. *Chest Imaging: (Include copy of chest x-ray and/or CT report with this request, CXR needs to be within 6 months) Date: Results: Normal Abnormal Cavitary If chest imaging is abnormal and consistent with TB, three sputum samples should be submitted to the WSLH for sme and culture, before treatment for LTBI can begin. E. *Prior treatment for tuberculosis infection or disease? NO YES Please explain: F. Baseline blood tests, if applicable (ALT/AST, CBC, CMP, T. BIL, if preexisting liver disease) Test Date Result						i i
D. *Chest Imaging: (Include copy of chest x-ray and/or CT report with this request, CXR needs to be within 6 months) Date: Results: Normal Abnormal Cavitary If chest imaging is abnormal and consistent with TB, three sputum samples should be submitted to the WSLH for sme and culture, before treatment for LTBI can begin. E. *Prior treatment for tuberculosis infection or disease? NO YES Please explain: F. Baseline blood tests, if applicable (ALT/AST, CBC, CMP, T. BIL, if preexisting liver disease) Test Date Result						
D. *Chest Imaging: (Include copy of chest x-ray and/or CT report with this request, CXR needs to be within 6 months) Date: Results: Normal Abnormal Cavitary If chest imaging is abnormal and consistent with TB, three sputum samples should be submitted to the WSLH for sme and culture, before treatment for LTBI can begin. E. *Prior treatment for tuberculosis infection or disease? NO YES Please explain: F. Baseline blood tests, if applicable (ALT/AST, CBC, CMP, T. BIL, if preexisting liver disease) Test Date Result		h				
Date: Results: _ Normal _ Abnormal _ Cavitary If chest imaging is abnormal and consistent with TB, three sputum samples should be submitted to the WSLH for sme and culture, before treatment for LTBI can begin. E. *Prior treatment for tuberculosis infection or disease? _ NO _ YES Please explain: F. Baseline blood tests, if applicable (ALT/AST, CBC, CMP, T. BIL, if preexisting liver disease) Test Date Result	O+					
Test Date Result	Ot	ner.	1			
	D. *Ch	nest Imaging: (Include of Dat Chest imaging is abnorm nd culture, before treatm ior treatment for tubero NO YES Please e	e: nal and consistent wi nent for LTBI can beg culosis infection or explain:	Results: ☐ Norr th TB, three sputum sampl jin. disease?	mal	tary
Test Date Result	D. *Ch	nest Imaging: (Include of Dat Chest imaging is abnorm nd culture, before treatm ior treatment for tubero NO YES Please e	e: nal and consistent wi nent for LTBI can beg culosis infection or explain:	Results: ☐ Norr th TB, three sputum sampl jin. disease?	mal	tary
	D. *CH If an E. *Pri	nest Imaging: (Include of Dat Chest imaging is abnormed culture, before treatment for tuberoom NO YES Please establine blood tests, if ap	e: nal and consistent with the control of the cont	Results: Norreth TB, three sputum samplin. disease? CBC, CMP, T. BIL, if pree	mal Abnormal Cavilles should be submitted to the	tary ne WSLH for sme
Test Date Result	D. *Ch If all E. *Pri F. Bas Test	nest Imaging: (Include of Dat Chest imaging is abnormed culture, before treatment for tubero NO YES Please esteline blood tests, if ap	e:e:e:e:e:e:e:e:e:e:e:	Results: Norr th TB, three sputum sampl gin. disease? CBC, CMP, T. BIL, if prec	mal Abnormal Caviles should be submitted to the existing liver disease)	tary ne WSLH for sme

Step 3- Wisconsin TB Program Review




If a regimen needs to be changed a new medication order should be submitted.




Step 4- Medication Refill




Many medication refills are automatic. Ask yourself...




Refill requests must be sent to the TB Program for active TB disease.




Many medication refills are automatic. Ask yourself...




Refill requests must be sent to the TB Program for liquid/compounded orders.




Many medication refills are automatic. Ask yourself...



An independent refill policy is needed if you are not using the TB Dispensary pharmacy.




If an automatic refill does not arrive, call the TB Program.



Please call the TB Program with any Dispensary pharmacy requests.

- Questions about medication or refill status
- Missing doses
- Expedited shipping
- Other special requests


Step 5- Treatment Follow-up



The completed follow-up form should be uploaded to WEDSS.

Active TB: <u>F-02474</u>

LTBI: <u>F-44125</u>





Reimbursement for Pharmacy Services using TOBI


An LHD may choose to contract with a local pharmacy for medications.










Access to pharmacy invoicing in TOBI is limited to LHDs with Attachment D filed.















TB Treatment Assistance Program

Wisconsin TB Treatment Assistance Program




Designed to encourage and support TB clients through the completion of TB treatment by providing funding to purchase treatment assistance aids.

Aids up to \$50 for LTBI patients and \$200 for active patients are available.




How to Use the TB Treatment Assistance Program



Extra assistance is available.

Special Request:

F-02461



Wisconsin Tuberculosis Program

Phone: 608-261-6319

Fax: 608-266-0049

email: dhswitbprogram@dhs.wisconsin.gov

https://www.dhs.wisconsin.gov/tb/index.htm



Questions?

